oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride

Phase 1Completed
0 watching 0 views this week💤 Quiet
32
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia

Conditions

Analgesia, Acute Pain, Chronic Pain, Narcotic Abuse, Opioid-related Disorders

Trial Timeline

Jul 1, 2010 → Sep 1, 2010

About oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride

oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloride is a phase 1 stage product being developed by Pfizer for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT01530542. Target conditions include Analgesia, Acute Pain, Chronic Pain.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01530542Phase 1Completed

Competing Products

20 competing products in Analgesia

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
52
HRF2105 patch + Loxoprofen patch + placeboJiangsu Hengrui MedicinePhase 2
52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
85
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
52
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
52
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
76
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
74
Experimental: stage I:HSK21542 0.4 μg/kg + Experimental: stage I:HSK21542 1 μg/kg + Experimental: stage I:HSK21542 0.5μg/kg + Experimental: stage I:HSK21542 1μg/kg + Experimental: stage II:HSK21542 0.5μg/kg + Experimental: stage II:HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
69
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
77
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
44
Bupivacaine HClHeron TherapeuticsApproved
77
HTX-011 + PlaceboHeron TherapeuticsPhase 2
44
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
69
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
77
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
44